FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Bush Tia L</u>						2. Issuer Name and Ticker or Trading Symbol Centessa Pharmaceuticals plc [CNTA]									k all app Direc	licable) tor	ng Pei	rson(s) to Is	vner	
(Last)	(Fir	st) (M		3. Date of Earliest Transaction (Month/Day/Year) 06/30/2024									Officer (give title below) Chief Technology & Quality				ofc			
3RD FL., 1 ASHLEY RD, ALTRINCHAM						4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	<u>·</u>					
(Street) CHESHIRE X0 WA14 2DT						Form filed by One Reporting Person Form filed by More than One Reporting Person														
(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
1. Title of Security (Instr. 3) 2. Transact Date (Month/Date)						Exec if any	Deemed cution Date, y nth/Day/Year)		3. Transaction Code (Instr. 8) 4. Securiti Disposed 5)		Disposed C	es Acquired (A) Of (D) (Instr. 3,) or 4 and		ties cially I Following	Forn (D) o	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) (D)	or Pr	ice		ed ction(s) 3 and 4)				
Ordinary Shares ⁽¹⁾ 06/30/2						2024					6,419(2)		\$	9.03	163,645			D		
		Tal									osed of, o				Owne	d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any	med 4. Transac Code (li Day/Year) 8)					6. Date Exerci Expiration Da (Month/Day/Yo		te	7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amour or Number of Shares	er						

Explanation of Responses:

- 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- 2. Represents the number of shares withheld by the Issuer to cover tax withhelding obligations in connection with the vesting of restricted share units.

Remarks:

/s/ Gregory Weinhoff, attorney-in-fact

07/02/2024

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.